Although the majority of p53 functional CLL primary samples exhibit a strong cytotoxic response to MDM2 inhibitors, a small subset of TP53WT CLL samples show an intermediate response or resistance to such treatments. Here, MDM2 is linked to B-cell chronic lymphocytic leukemia.